Executive summary The past six decades have seen remarkable improvements in health
outcomes for people with cystic fibrosis, which was once a fatal disease of infants and young …

Significant advances in the management of cystic fibrosis (CF) in recent decades have
dramatically changed the epidemiology and prognosis of this serious disease, which is no …

Newborn screening (NBS) for cystic fibrosis (CF) is increasingly being implemented and is
soon likely to be in use throughout the United States, because early detection permits …

Rationale: Better understanding of evolution of lung function in infants with cystic fibrosis
(CF) and its association with pulmonary inflammation and infection is crucial in informing …

Cystic fibrosis (CF) is a genetic disease with mutational changes leading to profound
dysbiosis, both pulmonary and intestinal, from a very young age. This dysbiosis plays an …

BACKGROUND: Cystic fibrosis (CF) is a recessively inherited condition caused by mutation
of the CFTR gene. Newborn infants with CF have raised levels of immuno-reactive …

Newborn screening (NBS) for cystic fibrosis (CF) has been performed in many countries for
as long as four decades and has transformed the routine method for diagnosing this genetic …

Background Hypophosphatasia (HPP) is a rare, systemic disease caused by mutation (s)
within the ALPL gene encoding tissue-nonspecific alkaline phosphatase (ALP). HPP has a …

Objective Cystic fibrosis (CF) can be difficult to diagnose, even when newborn screening
(NBS) tests yield positive results. This challenge is exacerbated by the multitude of NBS …

Background Newborn screening (NBS) algorithms for cystic fibrosis (CF) vary in the United
State of America and include different cystic fibrosis transmembrane conductance regulator …